Adverum Biotechnologies Inc ADVM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADVM is a good fit for your portfolio.
News
-
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
-
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
-
Thinking about buying stock in Adverum Biotechnologies, Roma Green Finance, Wah Fu Education, ESSA Pharma, or Science 37?
-
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
-
Thinking about buying stock in Gorilla Technology, Li Auto, Osisko Mining, Adverum Biotechnologies, or Kingsoft Cloud?
-
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
-
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
Trading Information
- Previous Close Price
- $11.15
- Day Range
- $10.92–11.34
- 52-Week Range
- $7.10–29.70
- Bid/Ask
- $4.51 / $11.34
- Market Cap
- $235.36 Mil
- Volume/Avg
- 138,898 / 299,385
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 31.23
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 121
- Website
- https://www.adverum.com
Comparables
Valuation
|
Metric
|
ADVM
|
SWTX
|
KDNY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.35 | 4.98 | 7.59 |
Price/Sales | 31.23 | 492.06 | 482.40 |
Price/Cash Flow | — | — | — |
Price/Earnings
ADVM
SWTX
KDNY
Financial Strength
|
Metric
|
ADVM
|
SWTX
|
KDNY
|
|---|---|---|---|
Quick Ratio | 3.87 | 6.21 | 5.72 |
Current Ratio | 4.13 | 6.41 | 5.82 |
Interest Coverage | — | — | — |
Quick Ratio
ADVM
SWTX
KDNY
Profitability
|
Metric
|
ADVM
|
SWTX
|
KDNY
|
|---|---|---|---|
Return on Assets (Normalized) | −41.62% | −39.61% | −37.41% |
Return on Equity (Normalized) | −75.76% | −45.43% | −47.73% |
Return on Invested Capital (Normalized) | −45.11% | −49.28% | −43.85% |
Return on Assets
ADVM
SWTX
KDNY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rcwdrydyy | Gvw | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wjtvvqp | Jthymj | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nsfqtqk | Sltyxs | $98.1 Bil | |
MRNA
| Moderna Inc | Lwcrdxgg | Jsh | $39.1 Bil | |
ARGX
| argenx SE ADR | Ctczvfyts | Fcdhm | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Zsmmjjj | Zht | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dptcdmvh | Kydkkmn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jcqzhswv | Sgkmb | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xmswmfgn | Lxytw | $12.5 Bil | |
INCY
| Incyte Corp | Bfqzbbcp | Slnhmnv | $11.9 Bil |